Mitigating immune toxicities associated with T cell-engaging cancer therapies

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the shift from chemotherapy to immunotherapy observed in multiple myeloma (MM) treatment, emphasizing that patients can often avoid chemotherapy at diagnosis and even during relapses. Prof. Landgren then highlights the potential use of an IL-6 receptor antagonist, such as tocilizumab, to reduce common immune toxicities associated with T cell-engaging therapies and potentially enable outpatient administration of these agents. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.